Anterix Sells Spectrum Assets to AT&T for $75M
Ticker: ATEX · Form: 8-K · Filed: Apr 23, 2024 · CIK: 1304492
Sentiment: neutral
Topics: asset-sale, telecom, spectrum
Related Tickers: T
TL;DR
Anterix selling its spectrum to AT&T for $75M. Big move.
AI Summary
Anterix Inc. announced on April 19, 2024, that it has entered into a definitive agreement to sell its spectrum licenses and related assets to an affiliate of AT&T Inc. for approximately $75 million in cash. This transaction is expected to close in the second half of 2024, subject to customary closing conditions.
Why It Matters
This sale represents a significant strategic shift for Anterix, potentially providing substantial capital while divesting core assets to a major telecommunications player.
Risk Assessment
Risk Level: medium — The transaction is subject to closing conditions, and the financial implications for Anterix post-sale are not fully detailed.
Key Numbers
- $75 million — Sale Price (Cash consideration for Anterix's spectrum licenses and related assets.)
Key Players & Entities
- Anterix Inc. (company) — Seller of spectrum assets
- AT&T Inc. (company) — Buyer of spectrum assets
- $75 million (dollar_amount) — Cash purchase price for spectrum assets
- April 19, 2024 (date) — Date of definitive agreement announcement
- second half of 2024 (date) — Expected closing period for the transaction
FAQ
What specific spectrum licenses and related assets are being sold to AT&T?
The filing states Anterix is selling its spectrum licenses and related assets, but does not provide a detailed list within this 8-K.
What are the specific closing conditions for this transaction?
The filing mentions 'customary closing conditions' but does not enumerate them.
What is Anterix's strategic plan following the sale of these assets?
This 8-K does not detail Anterix's future strategic plans beyond the sale.
Will AT&T be acquiring all of Anterix's spectrum, or a portion?
The filing indicates the sale of 'its spectrum licenses and related assets,' implying a significant portion or all of Anterix's holdings.
What is the expected impact of this sale on Anterix's ongoing operations?
The filing does not specify the impact on Anterix's ongoing operations, other than the divestiture of these assets.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-22 17:37:28
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value ATEX The Nasdaq Stock Market
Filing Documents
- atex-20240419.htm (8-K) — 30KB
- 0001304492-24-000042.txt ( ) — 154KB
- atex-20240419.xsd (EX-101.SCH) — 2KB
- atex-20240419_lab.xml (EX-101.LAB) — 22KB
- atex-20240419_pre.xml (EX-101.PRE) — 13KB
- atex-20240419_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 19, 2024, the Board of Directors (the " Board ") of Anterix Inc. (the " Company "), in consideration of setting the date of the 2024 Annual Meeting of Stockholders of the Company (the " 2024 Annual Meeting "), extended the date for stockholders to submit director nominations or proposals for consideration at the 2024 Annual Meeting. To be timely, stockholders have until June 30, 2024 to submit director nominations or proposals and otherwise comply with the requirements set forth in the Company's Amended and Restated Bylaws (the " Bylaws ") in order to have such director nominations or proposals considered for election or consideration at the 2024 Annual Meeting. The Board has neither modified the information or other procedural requirements contained to the Bylaws for director nominations or proposals nor extended the deadline for stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934. The Company intends to announce the date of the 2024 Annual Meeting after it is set by the Board.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Anterix Inc. Dat e: April 23, 2024 /s/ Gena L. Ashe Gena L. Ashe Chief Legal Officer and Corporate Secretary